![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF333 |
Gene summary for ZNF333 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF333 | Gene ID | 84449 |
Gene name | zinc finger protein 333 | |
Gene Alias | ZNF333 | |
Cytomap | 19p13.12 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q96JL9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84449 | ZNF333 | HCC1_Meng | Human | Liver | HCC | 4.22e-09 | 1.53e-02 | 0.0246 |
84449 | ZNF333 | HCC1 | Human | Liver | HCC | 1.23e-05 | 8.86e-01 | 0.5336 |
84449 | ZNF333 | HCC2 | Human | Liver | HCC | 1.77e-16 | 1.96e+00 | 0.5341 |
84449 | ZNF333 | HCC5 | Human | Liver | HCC | 1.56e-14 | 1.18e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
ZNF333 | CD8TEREX | Lung | AAH | KIAA1324,AL049779.4,FAM169A, etc. | 3.64e-02 | ![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF333 | SNV | Missense_Mutation | rs199652435 | c.484N>T | p.Arg162Cys | p.R162C | Q96JL9 | protein_coding | tolerated_low_confidence(0.05) | benign(0.18) | TCGA-A7-A4SC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ZNF333 | SNV | Missense_Mutation | c.727N>A | p.Ala243Thr | p.A243T | Q96JL9 | protein_coding | deleterious(0.01) | benign(0.014) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
ZNF333 | SNV | Missense_Mutation | c.1918N>T | p.His640Tyr | p.H640Y | Q96JL9 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-E2-A14S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | |
ZNF333 | SNV | Missense_Mutation | c.100G>C | p.Asp34His | p.D34H | Q96JL9 | protein_coding | deleterious(0) | possibly_damaging(0.811) | TCGA-GI-A2C8-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Adriamycin | SD | |
ZNF333 | insertion | Frame_Shift_Ins | novel | c.1534_1535insAGGT | p.Gly512GlufsTer25 | p.G512Efs*25 | Q96JL9 | protein_coding | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR | ||
ZNF333 | insertion | Nonsense_Mutation | novel | c.117_118insATGGAGATAAATGTCCTGTAAGGGTTTTGATTGT | p.Ala40MetfsTer7 | p.A40Mfs*7 | Q96JL9 | protein_coding | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
ZNF333 | insertion | Frame_Shift_Ins | novel | c.387_388insTTAGGGCAGGGGAAATATTGGCTGGGTGAGAGTGAGATAAG | p.Ala130LeufsTer28 | p.A130Lfs*28 | Q96JL9 | protein_coding | TCGA-B6-A0IE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
ZNF333 | SNV | Missense_Mutation | c.1870N>C | p.Glu624Gln | p.E624Q | Q96JL9 | protein_coding | tolerated(0.2) | possibly_damaging(0.8) | TCGA-C5-A7UE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
ZNF333 | SNV | Missense_Mutation | novel | c.494N>T | p.Trp165Leu | p.W165L | Q96JL9 | protein_coding | tolerated_low_confidence(0.31) | benign(0) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
ZNF333 | SNV | Missense_Mutation | novel | c.1267G>C | p.Glu423Gln | p.E423Q | Q96JL9 | protein_coding | tolerated(0.16) | possibly_damaging(0.856) | TCGA-VS-A9UR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |